<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01173081</url>
  </required_header>
  <id_info>
    <org_study_id>B3D-US-X026</org_study_id>
    <nct_id>NCT01173081</nct_id>
  </id_info>
  <brief_title>The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures</brief_title>
  <official_title>The Use of Teriparatide as an Adjunctive Therapy for the Treatment of Jones Fractures</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ohio Orthopedic Center of Excellence</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Eli Lilly and Company</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Ohio Orthopedic Center of Excellence</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized, placebo-controlled study will evaluate the effectiveness of the adjunctive
      use of teriparatide for the healing of Jones fractures.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2010</start_date>
  <completion_date type="Anticipated">April 2014</completion_date>
  <primary_completion_date type="Anticipated">April 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Fracture healing</measure>
    <time_frame>weeks 4 through 24 after start of treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pain</measure>
    <time_frame>weeks 4 through 24 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Range of Motion</measure>
    <time_frame>weeks 4 through 24 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Function</measure>
    <time_frame>weeks 4 through 24 after start of treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Return to Activity</measure>
    <time_frame>weeks 4 through 24 after start of treatment</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">38</enrollment>
  <condition>Fractures</condition>
  <arm_group>
    <arm_group_label>Teriparatide</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients randomized into this group will inject 20mcg of teriparatide once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Control</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Patients randomized into this group will inject a matching dose of placebo once daily for 16 weeks or until the study endpoint is achieved. Additionally, patients will take oral calcium (1,000mg) and vitamin D3 (1,000 IU) supplements daily.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Teriparatide</intervention_name>
    <description>20mcg once daily for 16 weeks or until study endpoint is achieved.</description>
    <arm_group_label>Teriparatide</arm_group_label>
    <other_name>Forteo</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>matching dose of 20mcg of placebo once daily for 16 weeks or until study endpoint is achieved</description>
    <arm_group_label>Placebo Control</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who are at least 18 years of age and who have closed epiphyses.

          -  Patients of both genders and all races.

          -  Patients with Jones fractures of the fifth metatarsal less than 2 weeks prior to
             presenting for clinical evaluation.

          -  Patients with a history of an acute injury and an acute Jones fracture defined by Torg
             et al as a fracture line with sharp margins without widening, absence of
             intramedullary sclerosis, and minimal or no cortical hypertrophy or evidence of
             periosteal changes due to chronic stress.

          -  Patients with either no prodromal symptoms or prodromal symptoms present less than 2
             weeks.

          -  Patients with a baseline visual analog scale (VAS) pain score â‰¤ 20 (100mm scale) for
             the fifth metatarsal, with the foot at rest and not bearing weight.

          -  Patients who are in good general health and who have physical examinations that either
             are within normal limits or are clinically non-significant as determined by the
             investigator.

          -  Patients with laboratory evaluations that either are within normal limits or are
             clinically non-significant as determined by the investigator.

          -  Patients who have voluntarily signed informed consent forms, including HIPAA
             Authorization.

        Exclusion Criteria:

          -  Patients who are younger than 18 years of age or patients who are 18 years of age or
             older with open epiphyses.

          -  Patients with Jones fractures of the fifth metatarsal greater than 2 weeks prior to
             presenting for clinical evaluation.

          -  Patients with tuberosity avulsion fractures or fifth metatarsal shaft fractures.

          -  Patients with prior fifth metatarsal fracture(s).

          -  Patients with prodromal symptoms present for more than 2 weeks.

          -  Patients with a nonunion or delayed union as defined by the radiographic criteria
             described by Torg et al.

          -  Patients who are allergic to any of the individual active ingredients in teriparatide
             or related compounds.

          -  Patients with chronic rheumatologic disease, ankylosing spondylitis or other
             inflammatory arthropathy.

          -  Patients with associated injuries considered by the investigator as to likely
             interfere with evaluation of the study drug.

          -  Patients with a present condition or history of any clinically significant
             gastrointestinal, cardiovascular, hepatic, renal, hematologic, endocrine, neurologic,
             psychiatric, connective tissue, respiratory or other medical disorders.

          -  Patients with Worker's Compensation claim(s) under dispute or mediation.

          -  Patients with history of drug or alcohol abuse.

          -  Patients who are pregnant or lactating.

          -  Patients who are considered by the investigator for any reason to be an unsuitable
             candidate for receipt of the study drug.

          -  Patients who are unwilling or unable to follow the follow-up evaluation schedules.

          -  Patients who refuse to voluntarily sign the informed consent form.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Peter H. Edwards, Jr., MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Ohio Orthopedic Center of Excellence</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Peter H. Edwards, Jr., MD</last_name>
    <phone>614-827-8700</phone>
    <email>LArnott@ohio-ortho.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Ohio Orthopedic Center of Excellence</name>
      <address>
        <city>Upper Arlington</city>
        <state>Ohio</state>
        <zip>43220</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lindsay Arnott, BS</last_name>
      <phone>614-827-8375</phone>
      <email>LArnott@ohio-ortho.com</email>
    </contact>
    <investigator>
      <last_name>Peter H. Edwards, Jr., MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Velimir Matkovic, MD, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 28, 2010</study_first_submitted>
  <study_first_submitted_qc>July 28, 2010</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 30, 2010</study_first_posted>
  <last_update_submitted>June 4, 2012</last_update_submitted>
  <last_update_submitted_qc>June 4, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 5, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Jones fracture</keyword>
  <keyword>fifth metatarsal fracture</keyword>
  <keyword>teriparatide</keyword>
  <keyword>fracture healing</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fractures, Bone</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Teriparatide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

